Psychiatric genetics and the future of personalized treatment

Depression and Anxiety

Volumn 31, Issue 11, 2014, Pages 893-898

  Smoller, Jordan W ^a,b,c  

^a Simches Research Center   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; DOPAMINE 2 RECEPTOR; ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMATINIB; ISRADIPINE; LOW DENSITY LIPOPROTEIN RECEPTOR; PCSK9 INHIBITOR; PSYCHOTROPIC AGENT; UNCLASSIFIED DRUG;

CALCIUM SIGNALING; DOPAMINE 2 RECEPTOR GENE; ETIOLOGY; GAIN OF FUNCTION MUTATION; GENETIC ASSOCIATION; GENETIC LINKAGE; HUMAN; MEDICAL GENETICS; MENTAL DISEASE; META ANALYSIS (TOPIC); NONHUMAN; NOTE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PSYCHIATRIC GENETICS; PSYCHIATRY; PSYCHOTHERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; GENETICS; MENTAL DISORDERS; PROCEDURES;

HUMANS; MENTAL DISORDERS; PHARMACOGENETICS;

EID: 84911362801     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22322     Document Type: Note

References (26)

1. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STARD: implications for clinical practice. Am J Psychiatry 2006; 163 (1): 28-40.
2. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353 (12): 1209-1223.
3. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006; 163 (2): 217-224.
4. Sullivan PF,. The psychiatric GWAS consortium: big science comes to psychiatry. Neuron 2010; 68 (2): 182-186.
5. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511 (7510): 421-427.
6. Malhotra D, Sebat J,. CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell 2012; 148 (6): 1223-1241.
7. Purcell SM, Moran JL, Fromer M, et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 2014; 506 (7487): 185-190.
8. Fromer M, Pocklington AJ, Kavanagh DH, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 2014; 506 (7487): 179-184.
9. Neale BM, Kou Y, Liu L, et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 2012; 485 (7397): 242-245.
10. Ripke S, O'Dushlaine C, Chambert K, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 2013; 45 (10): 1150-1159.
11. Major Depressive Disorder Working Group of the Psychiatric GC, Ripke S, Wray NR, et al. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry 2013; 18 (4): 497-511.
12. Duncan LE, Holmans PA, Lee PH, et al. Pathway analyses implicate glial cells in schizophrenia. PLoS One 2014; 9 (2): e89441.
13. Pedroso I, Lourdusamy A, Rietschel M, et al. Common genetic variants and gene-expression changes associated with bipolar disorder are over-represented in brain signaling pathway genes. Biol Psychiatry 2012; 72 (4): 311-317.
14. Nurnberger JI, Jr., Koller DL, Jung J, et al. Identification of pathways for bipolar disorder: a meta-analysis. JAMA Psychiatry 2014; 71 (6): 657-664.
15. Lee PH, Perlis RH, Jung JY, et al. Multi-locus genome-wide association analysis supports the role of glutamatergic synaptic transmission in the etiology of major depressive disorder. Transl Psychiatry 2012; 2: e184.
16. Uddin M, Tammimies K, Pellecchia G, et al. Brain-expressed exons under purifying selection are enriched for de novo mutations in autism spectrum disorder. Nat Genet 2014; 46 (7): 742-747.
17. Cross-Disorder Group of the Psychiatric Genomics C. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013; 381 (9875): 1371-1379.
18. Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014; 506 (7488): 376-381.
19. Dadu RT, Ballantyne CM,. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol 2014; 11 (10): 563-575.
20. Ostacher MJ, Iosifescu DV, Hay A, et al. Pilot investigation of isradipine in the treatment of bipolar depression motivated by genome-wide association. Bipolar Disord 2014; 16 (2): 199-203.
21. McGrath LM, Cornelis MC, Lee PH, et al. Genetic predictors of risk and resilience in psychiatric disorders: a cross-disorder genome-wide association study of functional impairment in major depressive disorder, bipolar disorder, and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2013; 162B (8): 779-788.
22. Chen CH, Lee CS, Lee MT, et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med 2014; 370 (2): 119-128.
23. Tansey KE, Guipponi M, Perroud N, et al. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med 2012; 9 (10): e1001326.
24. Investigators G, Investigators M, Investigators SD,. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry 2013; 170 (2): 207-217.
25. Tansey KE, Guipponi M, Hu X, et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry 2013; 73 (7): 679-682.
26. Lester KJ, Eley TC,. Therapygenetics: using genetic markers to predict response to psychological treatment for mood and anxiety disorders. Biol Mood Anxiety Disord 2013; 3 (1): 4.